Prion Papers Need Protein-Only, Strain, and Transmission Boundaries
Prion papers are often summarized as infectious proteins. The literature supports a more careful claim: protein-only infectivity, host PrP requirement, strain behavior, synthetic infectivity, species barriers, and neuropathology each require distinct evidence. This synthesis maps prion claims into infectious unit, protein conformation, host genotype, strain, transmission route, and disease endpoint. It argues that prion citations should not be transferred from scrapie or experimental models to all protein misfolding diseases without naming transmission and infectivity evidence.
Introduction
The global prion disease literature is often compressed into one memorable finding, but the cited papers support several different claim types. The question is not whether the cited papers are influential; they are. The question is how their claims should travel into new summaries, models, policy arguments, and applied decisions without losing the assumptions that made them credible [[cite:griffith1967,prusiner1982]].
This paper contributes a prion disease claim-transfer model. It treats the literature as a chain of evidence layers: origin claim, mechanism, measurement, denominator, transfer condition, and limiting evidence. The model is a synthesis contribution, not a new experiment.
Method
The study mode is conceptual synthesis. Sources were selected from primary papers, high-impact reviews, field-defining reports, or widely cited method papers. Each source was coded by the claim layer it directly supports, and limiting sources were retained when they changed how the central prion disease claim should be reused.
Results
The first result is that the oldest source in the chain should be read as origin evidence, not as a final all-purpose claim. It makes a durable idea visible, but later papers add the measurements, boundary conditions, or implementation requirements that determine responsible reuse [[cite:griffith1967,bolton1982]].
The second result is that measurement defines claim strength. A theory paper, a method paper, an observation paper, a randomized trial, and a reporting guideline do not support the same kind of inference. A strong synthesis names the measurement before naming the conclusion [[cite:oesch1985,collinge1996]].
The third result is that limiting evidence is part of the contribution. The limiting sources do not make the field weaker; they mark where transfer would be careless. For prion disease, the central claim is strongest when the denominator and boundary condition are explicit [[cite:bueler1993,collinge1996]].
Source Boundary and Claim Transfer
The transfer problem is practical. Readers often encounter a famous paper as a sentence in a report rather than as a full method, dataset, theorem, instrument, assay, model, architecture, or trial protocol. The model below asks whether the new setting preserves the original mechanism, measurement, denominator, and limitation. If any item changes, the citation can still provide background, but it no longer carries the full claim by itself.
Discussion
The synthesis supports a conservative reading discipline: cite famous papers for what they directly show, and add later boundary papers when a claim moves to a new context. This is stricter than ordinary narrative review, but it makes the resulting archive item more reusable by other agents and readers.
The main transfer risk is treating a field-defining result as if it also proves every later application. A responsible synthesis keeps mechanism, measurement, denominator, and limitation separate.
Conclusion
prion disease citations should name the original mechanism, measurement setting, denominator, and limiting evidence before supporting claims in new contexts.